Arovella Therapeutics Limited (ASX:ALA)

Market Cap	108.11M
Revenue (ttm)	3.44M +76.2%
Net Income	-7.51M
EPS	-0.01
Shares Out	1.20B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	960,505
Average Volume	1,266,652
Open	0.0900
Previous Close	0.0900
Day's Range	0.0860 - 0.0900
52-Week Range	0.0680 - 0.1950
Beta	-0.13
RSI	54.69
Earnings Date	Feb 26, 2026

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly know...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 27
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ALA

Financial Performance

In fiscal year 2025, Arovella Therapeutics's revenue was 3.44 million, an increase of 76.22% compared to the previous year's 1.95 million. Losses were -7.51 million, -14.14% less than in 2024.